Michael Wolff Jensen
General Counsel bij ASCENDIS PHARMA A/S
Vermogen: 291 909 $ op 31-03-2024
Profiel
De heer Michael Wolff Jensen is voorzitter bij Vicore Pharma Holding AB, Chief Executive Officer bij Miwo Invest ApS, voorzitter bij Xspray Pharma AB, voorzitter bij Ascendis Pharma Endocrinology Division A/S, voorzitter, Chief Legal Officer & Senior VP bij Ascendis Pharma A/S, voorzitter bij Ascendis Pharma Bone Diseases A/S en voorzitter bij Ascendis Pharma Growth Disorders AS. Hij zit in de Raad van Bestuur van Visen Pharmaceuticals (Shanghai) Co. Ltd. De heer Jensen was voorheen werkzaam als voorzitter bij Eurocine Vaccines AB, als hoofd France Partnerships bij DONG Energy A/S, als Chief Financial Officer & Executive Vice President bij LifeCycle Pharma A/S, als Chief Financial Officer & Senior Vice President bij Genmab A/S, als President & Chief Executive Officer bij EMF Industries A/S, als voorzitter bij MWJ Invest AB, als voorzitter bij Paradis A/S en als voorzitter bij Vanx ApS. Hij was ook lid van de raad van bestuur van Azanta A/S. Hij is afgestudeerd aan de Universiteit van Kopenhagen.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ASCENDIS PHARMA A/S
0.00% | 31-12-2023 | 1 931 ( 0.00% ) | 291 909 $ | 31-03-2024 |
Actieve functies van Michael Wolff Jensen
| Bedrijven | Functie | Begin |
|---|---|---|
| ASCENDIS PHARMA A/S | General Counsel | 01-06-2013 |
Miwo Invest ApS
 Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Chief Executive Officer | 28-01-2014 |
| Ascendis Pharma Ophthalmology Division A/S | Chairman | - |
| Ascendis Pharma, Inc. | Director/Board Member | - |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Chairman | 08-01-2021 |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Chairman | - |
| Ascendis Pharma Growth Disorders AS | Chairman | - |
| Ascendis Pharma Bone Diseases A/S | Chairman | - |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Board Member | 01-05-2021 |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Michael Wolff Jensen
| Bedrijven | Functie | Einde |
|---|---|---|
| ░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Michael Wolff Jensen
| University of Copenhagen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| EUROCINE VACCINES AB | Health Technology |
| GENMAB A/S | Health Technology |
| ORSTED A/S | Utilities |
| ASCENDIS PHARMA A/S | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| Bedrijven in privébezit | 16 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
| Paradis A/S | |
| EMF Industries A/S | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Health Technology |
| MWJ Invest AB | |
| Ascendis Pharma, Inc. | |
Miwo Invest ApS
Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Commercial Services |
| Vanx ApS | |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
| Ascendis Pharma Bone Diseases A/S | |
| Ascendis Pharma Ophthalmology Division A/S | |
| Ascendis Pharma Oncology Division A/S | |
| Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
